Virtual Intelligence for Transformative Lifestyle Solutions in Pain
ConditionChronic Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMontefiore Medical Center
About this trial
This pilot study aims to evaluate the feasibility and acceptability of a VR-based chronic pain management intervention with a virtual AI coach for patients with Opioid misuse and opioid use disorder (OM/OUD). The intervention is a single-day 45-minute VR intervention which is subdivided into three smaller sessions:
Session 1: A 15-minute AI check-in to ask questions about biopsychosocial health, Session 2: A 20-minute Pain Coping Skills Training (PCST) session offering psychoeducation on managing chronic pain Session 3: A 10-minute stress reduction exercise.
The VR sessions will be conducted using hardware (VR Headset Device - Meta Quest 3) and software developed by AugMend Health Company.
The study will be conducted in a clinical setting at the Montefiore Multidisciplinary Pain Medicine Program (MMPP), a Pain Medicine outpatient specialty practice within a major urban medical center. MMPP providers see thousands of patients every month, some of which have concurrent opioid misuse or OM/OUD.
Eligibility criteria
Qualifiers
Patients with opioid misuse or International Classification of Diseases 10th revision (ICD-10) diagnosis of opioid use disorder
Patients with Chronic pain of at least moderate intensity (>4 Pain Intensity Score) with no pain medication changes in 14 days
Ability to understand written/spoken instruction and provide informed consent in English
Ability and willingness to participate in all components of the study
Disqualifiers
History of severe motion sickness, cybersickness, or conditions that could make participation in VR hazardous or cause adverse effects
Conditions that could prevent proper use of VR headset (such as vision problems that cannot be corrected by contact lenses or glasses that fit in VR, Significant hearing impairments that cannot be corrected by a hearing device)
History of seizures or seizure disorder
Acute exacerbation of psychiatric conditions such as self-injurious behaviors or suicidal risk that preclude the ability to participate in the study
Trial design
Treatments tested in this trial
- VR Headset Device - Meta Quest 3
Treatment groups
15 Participants
are divided into 1 treatment groupLocations
1Montefiore Multidisciplinary Pain Medicine Program (MMPP) at Montefiore Einstein Hutchinson Campus10467, The BronxNew York, United States
Sponsors and collaborators
Montefiore Medical Center
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
AugMend Health
Collaborator
Source ClinicalTrials.gov